NCT05682807

Effect of Caffeine Versus Probiotic on Preterm Neonates With Bronchopulmonary Dysplasia

Name: Clinical Trial NCT05682807
Creator: Tanta University
Keywords: Bronchopulmonary Dysplasia, Caffeine, Phase 3, drug, clinical trial, Egypt

Caffeine Versus Probiotic as Adjuvant Therapy for Preterm Neonates With Bronchopulmonary Dysplasia

Tanta University·Phase 3·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Bronchopulmonary Dysplasia
Drug/Device/Intervention: Caffeine
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Tanta University
Location: Tanta, Egypt

Timeline & enrollment

Phase: Phase 3
Start date: Jun 30, 2022
End date: Jun 01, 2025
Enrollment: 90 participants

Primary outcome

Complete blood count,Kidney function test,Liver function test,Inflammatory parameter

Summary

The aim of this study is to evaluate the effectiveness of caffeine versus probiotics supplementation as adjuvant therapy for preterm neonates with Bronchopulmonary dysplasia (BPD).

ICD-10 classifications

Bronchopulmonary dysplasia originating in the perinatal periodCongenital bronchomalaciaBronchopneumonia, unspecifiedOther congenital malformations of bronchusDiseases of bronchus, not elsewhere classified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05682807
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05682807 through Pure Global AI's free database. This Phase 3 trial is sponsored by Tanta University and is currently Recruiting. The study focuses on Bronchopulmonary Dysplasia. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.